Ondřej Skořepa

Ondřej Skořepa

Auto-generated profile, based on publicly available information

Ondřej Skořepa

Department of Biochemistry, Faculty of Science, Charles University, Hlavova 2030/8, 12840, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
IPIsabelle Pachmayr
Isabelle Pachmayr
LMLuciano A. Masullo
Luciano A. Masullo
SRSusanne C. M. Reinhardt
Susanne C. M. Reinhardt
JKJisoo Kwon
Jisoo Kwon
MLMaite Llop
Maite Llop
RJRalf Jungmann
Ralf Jungmann
Monoclonal antibodies (mAb) are key therapeutic agents in cancer immunotherapy and exert their effects through Fc receptor-dependent and -independent mechanisms. However, the nanoscale receptor reorganization resulting from mAb binding and its implications for the therapeutic mode of action remain poorly understood. Here, we present a multi-target 3D RESI super-resolution microscopy technique that directly visualizes the structural organization of CD20 receptors and the Type I (e.g., Rituximab) and Type II (e.g., Obinutuzumab) anti-CD20 therapeutic antibodies and quantitatively analyze these interactions at single-protein resolution in situ. We discover that, while Type I mAbs promote higher-order CD20 oligomerization, Type II mAbs induce limited clustering, leading to differences in therapeutic function. Correlating RESI with functional studies for Type II antibodies with different hinge region flexibilities, we show that the oligomeric CD20 arrangement determines the Type I or Type II function. Thus, the nanoscale characterization of CD20-mAb complexes enhances our understanding of the structure-function relationships of therapeutic antibodies and offers insights into the design of next-generation mAb therapies.

1 December 2017 in Protein Expression and Purification
Verified
Journal Article
Closed access
JBJan Bláha
Jan Bláha
BKBarbora Kalousková
Barbora Kalousková
OSOndřej Skořepa
Ondřej Skořepa
SPSamuel Pažický
Samuel Pažický
Petr NovakPetr Novak
Petr Novak
Ondrej VanekOndrej Vanek
Ondrej Vanek

28 November 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Ondrej VanekOndrej Vanek
Ondrej Vanek
PCPetra Celadova
Petra Celadova
OSOndřej Skořepa
Ondřej Skořepa
JBJan Bláha
Jan Bláha
BKBarbora Kalousková
Barbora Kalousková
JCJames R. Carlyle
James R. Carlyle
Working at the border between innate and adaptive immunity, natural killer (NK) cells play a key role in the immune system by protecting healthy cells and by eliminating malignantly transformed, stressed or virally infected cells. NK cell recognition of a target cell is mediated by a receptor “zipper” consisting of various activating and inhibitory receptors, including C-type lectin-like receptors. Among this major group of receptors, two of the largest rodent receptor families are the NKR-P1 and the Clr receptor families. Although these families have been shown to encode receptor-ligand pairs involved in MHC-independent self-nonself discrimination and are a target for immune evasion by tumour cells and viruses, structural mechanisms of their mutual recognition remain less well characterized. Therefore, we developed a non-viral eukaryotic expression system based on transient transfection of suspension-adapted human embryonic kidney 293 cells to produce soluble native disulphide dimers of NK cell C-type lectin-like receptor ectodomains. The expression system was optimized using green fluorescent protein and secreted alkaline phosphatase, easily quantifiable markers of recombinant protein production. We describe an application of this approach to the recombinant protein production and characterization of native rat NKR-P1B and Clr-11 proteins suitable for further structural and functional studies.

16 June 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
JBJan Bláha
Jan Bláha
TSTereza Skálová
Tereza Skálová
BKBarbora Kalousková
Barbora Kalousková
OSOndřej Skořepa
Ondřej Skořepa
DCDenis Cmunt
Denis Cmunt
Ondrej VanekOndrej Vanek
Ondrej Vanek
Human NKR-P1 (CD161, KLRB1 ) and its ligand LLT1 ( CLEC2D ) are a prototypical inhibitory C-type lectin-like receptor:ligand pair of NK cells with a critical role in homing lymphocytes to immune-privileged sites, particularly in multiple sclerosis, rheumatoid arthritis, and Crohn’s disease. Furthermore, NKR-P1:LLT1 inhibitory signaling is associated with glioblastoma, non-Hodgkin’s lymphoma, breast, and prostate cancer. However, the lack of structural data on the formation of the NKR-P1:LLT1 complex limits our understanding of this signaling. We thus solved the crystal structures of NKR-P1 and the NKR-P1:LLT1 complex. NKR-P1 forms a homodimer with an unexpected arrangement that enables LLT1 binding in two modes, bridging two LLT1 molecules, thereby forming interaction clusters suggestive of an inhibitory immune synapse. Moreover, observing the formation of these clusters by SEC-SAXS analysis in solution and by dSTORM super-resolution microscopy on the cell surface, and following their role in receptor signaling using in vitro cytotoxicity assay with freshly isolated NK cells, we show how NKR-P1:LLT1 clustering allows these proteins to overcome the weak affinity of C-type lectin-like receptors to their ligands. Furthermore, only the ligation of both primary and secondary LLT1 binding interfaces leads to effective NKR-P1 inhibitory signaling. Therefore, our findings show how inhibitory receptor cross-linking and clustering work together to trigger signal transduction upon cellular contact in the immune synapse.

13 February 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Ondrej VanekOndrej Vanek
Ondrej Vanek
PCPetra Celadova
Petra Celadova
OSOndřej Skořepa
Ondřej Skořepa
JBJan Bláha
Jan Bláha
BKBarbora Kalousková
Barbora Kalousková
JCJames R. Carlyle
James R. Carlyle
An amendment to this paper has been published and can be accessed via a link at the top of the paper.